Shah Manish A
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Curr Oncol Rep. 2002 May;4(3):193-201. doi: 10.1007/s11912-002-0016-0.
Surgery remains the mainstay for the curative treatment of gastric carcinoma. However, despite adequate surgery, survival remains poor. The use of adjuvant chemotherapy and radiotherapy has been examined in multiple previous clinical trials without convincing evidence of efficacy. However, recently, a large randomized controlled Intergroup trial, INT 116, demonstrated a survival advantage with chemoradiotherapy following curative surgery for gastric cancer. This review discusses the merits of the Intergroup trial and the ways in which it should affect the treatment of gastric cancer in the United States. INT 116 provides a foundation on which we can build to improve the care of patients with gastric cancer. With the evaluation of potentially better chemotherapeutic agents and the advent of molecularly directed therapy, there is increasing hope for improving the care of patients with gastric carcinoma.
手术仍然是胃癌根治性治疗的主要手段。然而，尽管进行了充分的手术，患者的生存率仍然很低。之前的多项临床试验已对辅助化疗和放疗的应用进行了研究，但均未找到令人信服的疗效证据。不过，最近一项大型随机对照多中心试验（INT 116）表明，胃癌根治性手术后进行放化疗可提高生存率。本文综述了该多中心试验的优点以及它对美国胃癌治疗可能产生的影响。INT 116为我们改善胃癌患者的治疗提供了一个基础。随着对潜在更好的化疗药物的评估以及分子靶向治疗的出现，改善胃癌患者治疗的希望越来越大。
